H. Lundbeck, Lundbeck and Forest updates Lexapro® patent litigation status

H. Lundbeck A/S and Forest Laboratories, Inc. announced today that pursuant to a joint status update entered into the public docket in the US District Court for the District of Delaware, the Company and defendant Alphapharm Pty Ltd. have advised the Court that they have signed a term sheet and are negotiating in good faith towards a full resolution of their pending patent infringement dispute regarding U.S. Patent Re. No. 34,712, which relates to Forest’s Lexapro® (escitalopram oxalate) product.